¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"non per os"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • non-neurogenic neuropathic bladder
    ºñ½Å°æ½Å°æº´¼º¹æ±¤
  • non-proprietary name
    ÀϹݸí
  • non-Q wave
    ºñQÆÄ
  • non-rapid eye movement
    ºñ±Þ¼Ó¾È±¸¿îµ¿
  • non-small cell carcinoma
    ºñ¼Ò¼¼Æ÷¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • non-lysosomal proteinase
    ºñ¸®¼Ò¼Ø´Ü¹éºÐÇØÈ¿¼Ò
  • non-proprietary name
    ÀϹݸí
  • non-vibrating tinnitus
    ºñÁøµ¿±Í¿ï¸², ºñÁøµ¿À̸í
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • parts per million
    ¹é¸¸ºÐÀÇ
  • parts per million =ppm
    ¹é¸¸ºÐÀ²(ËÑËÎ ËÓËô).
  • per anum ³ª
    °æÇ×¹®Àû(ÌèùýÚ¦îÜ)ÀÎ.
  • per clysma ³ª
    °üÀå(δ ).
  • per primam intentionem <³ª>
    Á¦ÀÏÂ÷Ä¡À¯(Á¦ÀÏÂ÷Ä¡À¯)ÀÇ.
  • per tertian intentionem
    Á¦»ïÂ÷(Á¦»ïÂ÷)Ä¡À¯ÀÇ.
  • per tuba
    À̰üÀ» ÅëÇØ
  • per. dev. dis., Aspergers disorder
    Àü¹ÝÀû ¹ß´ÞÀå¾Ö, ¾Æ½ºÆÛ°Å ÁõÈıº
  • per. dev. dis., Retts disorder
    Àü¹ÝÀû ¹ß´ÞÀå¾Ö, ·¹Æ® ÁõÈıº
  • per. dev. dis., autistic disorder
    Àü¹ÝÀû ¹ß´ÞÀå¾Ö, ÀÚÆóÀå¾Ö(º´)
  • per. dev. dis., childhood disintegrative disorder
    Àü¹ÝÀû ¹ß´ÞÀå¾Ö, ¼Ò¾Æ±â(¾Æµ¿±â) ºØ±«¼º Àå¾Ö(º´)
  • revolution per minute =rpm
    ºÐ´çȸÀü¼ö.
  • conditio sine qua non
    Àý´ëÇÊ¿äÁ¶°Ç(ËøËÀ̰Ëí̡˧).
  • conditio sine qua non
    Àý´ëÇÊ¿äÁ¶°Ç(ï¾Óßù±é©ðÉËì).
  • diabetes mellitus,non-insulin-dependent
    ºñ-Àν¶¸° ÀÇÁ¸¼º(Þª¡­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NPO Nulli(Non) Per Os; Nothing by Mouth; ±Ý½Ä
AAPCC adjusted annual per capita cost; adjusted average per capita cost; American Association of Poison Co...
BPM beats per minute; biperidyl mustard; breaths per minute; brompheniramine maleate
cpm counts per minute; cycles per minute
cps counts per second; cycles per second
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NANC Non-adrenergic non-cholinergic
non-LTR Non-long terminal repeat
non-REM Non-rapid eye movement
non-REMS Non-rapid eye movement sleep
non-SCLC Non-small cell lung cancers
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • non odontogenic cyst
    ºñ Ä¡¼º ³¶
  • non- pressure impression
    ¹«¾Ð Àλó
  • non-adjustable articulator
    ºñÁ¶Àý¼º ±³ÇÕ±â
    ȯÀÚÀÇ ÇϾǰñ ¿îµ¿À» ¿ÏÀüÈ÷ ÀçÇö½Ãų ¼ö ¾ø´Â ±³ÇÕ±â.
  • non-anatomical porcelain teeth
    ºñÇØºÎÇÐÀû µµÄ¡
    ÀÚ¿¬Ä¡¿Í Á¶±Ýµµ À¯»çÇÏÁö ¾Ê°í ±âÇÏÇÐÀûÀ¸·Î ¼ºÇüµÈ ÇüŸ¦ °¡Áö´Â ´õ¿íÀÌ ÃÑÀÇÄ¡ÀÇ ±³ÇÕ¿¡ Á¶È­µÇµµ·Ï ¸¸µé¾îÁø ±¸Ä¡ºÎ¿ëÀÇ ÀΰøÄ¡.
  • non-caseating epithelioid cell granulomata
    ºñ°Ç¶ô¼º À¯»óÇÇ ¼¼Æ÷ À°¾ÆÁ¾
  • non-centric cusp tip
    ºñÁ᫐ ±³µÎÁ¤
  • non-cleft side
    ºñ±¸°³¿­Ãø
  • non-dental pain
    ºñÄ¡¼º ÅëÁõ
  • non-enhanced image
    ºñÁ¶¿µ Áõ°­ ¿µ»ó
  • non-Hodgkin lymphoma
    ºñÈ£ÁöŲ ¸²ÇÁÁ¾
  • non-inflammatory
    ºñ¿°Áõ¼º
  • non-injury controlled population
    ºñ¿Ü»ó¼º ȯÀÚ
  • non-invasive
    ºñ°üÇ÷Àû, ºñħ¹ü¼º
  • non-keratinized squamous cell carcinoma
    ºñ°¢È­¼º ÆíÆò »óÇÇ ¼¼Æ÷ ¾Ï
  • non-malignant
    ºñ¾Ç¼º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
per vias naturales Through the natural passages; e.g., denoting a normal delivery, as opposed to cesarean section, or the passage in stool of a foreign body instead of its surgical removal.
Origin: L.
(05 Mar 2000)
haemorrhage per rhexis Haemorrhage due to the rupture of a blood vessel.
(05 Mar 2000)
cycles per second The number of successive compressions and rarefactions per second of a sound wave. The preferred designation for this unit of frequency is hertz.
Acronym: cps
(05 Mar 2000)
Scholander, Per <person> Norwegian physiologist, 1905-1980.
See: Scholander apparatus, Roughton-Scholander apparatus, Roughton-Scholander syringe.
(05 Mar 2000)
displacements per atom (dpa) This is a measure of the amount of radiation damage in neutron-irradiated materials, for example, 10 dpa means each atom in the material has been displaced from its site within the structural lattice of the material an average of 10 times (due to interactions between the atoms and the energetic neutrons irradiating the material.)
(09 Oct 1997)
Ling, Per Henrik <person> Swedish hygienist, 1776-1839.
See: Ling's method.
(05 Mar 2000)
abortifacient agents, non-steroidal Non-steroidal chemical compounds with abortifacient activity.
(12 Dec 1998)
acute non-lymphocytic leukaemia <haematology> A form of leukaemia which is characterised by the proliferation of immature bone marrow precursor cells in the marrow and immature white blood cells (granulocytes) in the bloodstream. Occurs primarily in adults and in infants under 1 year of age. Complications include abnormal bleeding and susceptibility to infections.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Trisomy-8 is the most common cytogenetic abnormality observed, followed by monosomy-7 and monosomy-5. Approximately 8% of cases show trisomy-8, mostly in AML (M1), AM (M4) and acute monocytic leukaemia (M5). Many pre-leukaemic conditions, acute non-lymphocytic leukaemia and secondary leukemia show monosomy-7 or deletion of the long arm of chromosome 7.
Treatment includes chemotherapy and/or bone marrow transplant.
Acronym: ANLL
Incidence: 2.5 cases per 100,000 (all ages).
Origin: Gr. Haima = blood
(07 Apr 1998)
analgesics, non-narcotic Drugs that have principally analgesic, antipyretic, and anti-inflammatory actions. They do not bind to opioid receptors and are not classified under the controlled substances act.
(12 Dec 1998)
anti-inflammatory agent, non-steroidal Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5)
(12 Dec 1998)
auctorum non Not of authors.
(09 Jan 1998)
cancer, lymphoma, non-hodgkin's A lymphoma is a cancer that develops in the lymphatic system. The most common symptom of non-Hodgkin's lymphomas is a painless swelling in the lymph nodes in the neck, underarm, or groin. Non-Hodgkin's lymphomas are diagnosed with a biopsy of an enlarged lymph node. Follow-up examinations are important after lymphoma treatment. Most relapses occur in the first 2 years after therapy.
(12 Dec 1998)
carcinoma, non-small-cell lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. They are dealt with collectively because of the shared properties of poor response to conventional chemotherapy and the potential for cure with surgical resection in a fraction of patients.
(12 Dec 1998)
Gomori's non-specific acid phosphatase stain <technique> A method in which formalin-fixed frozen sections are incubated in a substrate containing sodium beta-glycerophosphate and lead nitrate at pH 5.0; the insoluble lead phosphate produced is treated with ammonium sulfide to give a black lead sulfide.
(05 Mar 2000)
Gomori's non-specific alkaline phosphatase stain <technique> A calcium-cobalt sulfide method using frozen sections or cold acetone-or formalin-fixed paraffin sections, plus sodium beta-glycerophosphate as a substrate at pH 9.0 to 9.5 with Mg++ as activator; calcium ions precipitate the liberated phosphate, cobalt salt replaces the calcium phosphate, and ammonium sulfide converts the product to a black cobalt sulfide.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • per procurationem
    ´ë¸®·Î
  • per sep
    ±× ÀÚü;º»ÁúÀûÀ¸·Î´Â
  • per.
    period;person
  • price per unit
    (»óǰÀÇ) ÇÒÀÎ ÀüÀÇ ´Ü°¡;(īŻ·Î±× µî¿¡ ³ª¿Í ÀÖ´Â) ÆÇ¸Å Èñ¸Á °¡°Ý
  • non sequitur
    ±×¸©µÈ °á·Ð
  • non-essential
    ºñº»ÁúÀûÀÎ
  • non-homogeneous
    ÀÌÁúÀÇ
  • dies non
    (L)(¹ý)ÈÞÁ¤ÀÏ;À¯¾÷ÀÏ
  • non Euclidean
    ºñ À¯Å¬¸®µåÀÇ
  • non assumpsit
    (¹ý)Àμö¼Ò¼Û(assumpsit)¿¡¼­ÇǰíÀÇ °è¾à ºÎÀÎÀÇ ´äº¯
  • non compos(mentis)
    ¿ÇÀº Á¤½ÅÀÌ ¾Æ´Ñ;Á¤½ÅÀÌ»óÀÇ(insane)
  • non est
    Á¸ÀçÇÏÁö ¾Ê´Â;ºÎÀçÀÇ
  • non est inventus
    º»ÀμÒÀç ºÒ¸í
  • non liquet
    ÀçÆÇ ¿¬±âÀÇ ¹è½ÉÆò°á
  • non obs(t).
    non obstante
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á